Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 3/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 4/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22437335 | 0.87 | MAPT (0.37) | PIK3CAPIK3R1AURKAAURKBKDR | |
| SCHEMBL16046405 | 0.82 | CFTR (0.41) | AURKAAURKBKDRGLAPOLB | |
| SCHEMBL21940465 | 0.80 | ALDH1A1 (0.47) | AURKAAURKBKDRGLAPOLB | |
| SCHEMBL5942469 | 0.79 | AURKA (0.42) | PIK3CAPIK3R1AURKAAURKBKDR | |
| SCHEMBL24968411 | 0.78 | AURKA (0.41) | PIK3CAPIK3R1AURKAAURKBKDR | |
| SCHEMBL115676 | 0.78 | AURKA (0.41) | PIK3CAPIK3R1AURKAAURKBKDR | |
| SCHEMBL30851311 | 0.78 | SSTR4 (0.42) | PIK3CAPIK3R1AURKAAURKBKDR | |
| SCHEMBL30851250 | 0.78 | AURKA (0.41) | PIK3CAPIK3R1AURKAAURKBKDR | |
| SCHEMBL322071 | 0.78 | SSTR4 (0.42) | PIK3CAPIK3R1AURKAAURKBKDR | |
| SCHEMBL24656388 | 0.76 | PIK3R1 (0.41) | PIK3CAPIK3R1AURKAAURKBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022234271-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| EP-3601254-B1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3430005-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE | PLEXXIKON INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11130751-B2 | Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-28 | — | — | US | disclosed |
| US-20200181132-A1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS | NOVALIX (FR) | 2020-06-11 | — | — | US | disclosed |
| EP-3601254-A1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS | Janssen Pharmaceutica NV (BE) | 2020-02-05 | — | — | EP | disclosed |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | NOVARTIS AG (CH) | 2019-10-15 | — | — | US | disclosed |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | NOVARTIS AG (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3149001-B1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3R1 9/4885AURKA 765/4885 |
| US-20200181132-A1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 11/4885AURKA 629/4885 |
| US-11130751-B2 | Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 12/4885AURKA 665/4885 |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | PIK3CA 2042/4885PIK3R1 1641/4885AURKA 4004/4885 |
| US-10442808-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors | FBP1, MMEL1, MALT1 | PIK3CA 1473/4885PIK3R1 1800/4885AURKA 4112/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3R1 9/4885AURKA 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.